You are here: Industry Insights > SARS-CoV-2

News List

Study notes COVID-19 most likely caused by animal source, not of lab origin expresspharma
July 12, 2021
The study noted that while a laboratory accident "cannot be entirely dismissed", there currently exists zero evidence for such a lab origin of the virus behind the COVID-19 pandemic.
Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist firstwordpharma
July 12, 2021
Viral vector and mRNA vaccines, including Russia's Sputnik V, provide enough protection against the new Delta strain of the coronavirus, albeit to a lesser extent, reported The Times of India.
COVID-19 Treatment Clinical Landscape Research Report 2021: Pandemic Perspectives - US FDA Wastes No Time In COVID-19 Emergency Use Authorization Reviews prnewswire
July 12, 2021
The commercial outlook for COVID-19 therapeutics is expected to decline progressively throughout 2021 due to the phased implementation of global vaccination programs, which should substantially reduce both outpatient and hospital COVID-19 cases.
Animal Extremists Exploit COVID Fears to Propose Ban on U.S. Mink Farming, says Fur Commission USA prnewswire
July 12, 2021
Connecticut Representative Rosa DeLauro (D-CT) has introduced a bill to amend the Lacey Act of 1981, HR 4310, to ban all "import, export, transport, sale, receipt, acquirement, or purchase in interstate or foreign commerce of mink, and for other purposes.
QUT discovers new anticoagulant drug target for Covid-19 pharmaceutical-technology
July 09, 2021
A research team at the Queensland University of Technology (QUT) in Australia has discovered a new binding site on the SARS-CoV-2 spike (S) protein, which could be used as a target for anticoagulant drugs.
Exscientia receives $1.5m Gates Foundation grant for AI-designed Covid-19 drugs pharmaceutical-technology
July 09, 2021
UK-based artificial intelligence (AI) drug discovery company Exscientia has received a $1.5m grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners to accelerate the development of a new class of Covid-19 drugs.
Centers for Disease Control and Prevention (CDC) Releases Study on Physical Health and Functional Status Among Patients Referred to Outpatient Rehabilitation Clinics After COVID-19 Diagnosis prnewswire
July 09, 2021
Former COVID-19 patients may benefit from additional clinical support, including tailored physical and mental health rehabilitation services, according to a study released today by The Centers for Disease Control and Prevention (CDC).
Eurofins Viracor Invests in Innovation with the Launch of Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Testing prnewswire
July 09, 2021
As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT™ T Cell Immunity testing.
Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response worldpharmanews
July 08, 2021
Johnson & Johnson announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.
Protein spikes developed in labs consistent with COVID-19 virus expresspharma
July 08, 2021
The manufacture of protein "spikes" is key to designing serological tests and vaccines against COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page